Table 2 Basic characteristics of patients in two groups in propensity-matched dataset

Demographics

 Female, n (%)

45 (25.57)

37 (21.02)

0.254

 Age, year (IQR)

65.00 (59.75–71.00)

66.00 (58.00–71.25)

0.827

 BMI, kg/m² (IQR)

25.46 (24.04–27.73)

26.17 (24.60–28.16)

0.179

 Smoking status, n (%)

92 (52.27)

95 (53.98)

0.749

 Drinking status, n (%)

89 (50.57)

98 (55.11)

0.336

 SBP, mmHg (IQR)

125.00 (114.00–139.00)

124.50 (115.75–140.00)

0.619

 DBP, mmHg (IQR)

71.50 (65.00–78.00)

71.00 (64.00–80.00)

0.556

 HR, bpm (IQR)

68.00 (64.00–72.00)

68.00 (64.00–72.00)

0.394

 LVEF, % (IQR)

58.00 (58.00–64.00)

60.00 (56.00–65.00)

0.867

Comorbidities

 Previous MI, n (%)

40 (22.73)

49 (27.84)

0.270

 Previous PCI, n (%)

34 (19.32)

36 (20.46)

0.789

 Previous CABG, n (%)

3 (1.71)

4 (2.27)

1.000

 Hypertension, n (%)

127 (72.16)

137 (77.84)

0.051

 AF, n (%)

13 (7.39)

13 (7.39)

1.000

 HF, n (%)

11 (6.25)

15 (8.52)

0.415

 Hyperlipemia, n (%)

146 (82.96)

145 (82.39)

0.888

 Ischemic stroke, n (%)

21 (11.93)

19 (10.80)

0.737

 Previous cerebral hemorrhage, n (%)

0

1 (0.57)

1.000

 COPD, n (%)

0

2 (1.14)

0.499

Laboratory variables

 hs-TNI, pg/ml (IQR)

10.45 (5.18–21.08)

10.10 (5.30–17.83)

0.451

 BNP, pg/ml (IQR)

50.49 (22.15–116.49)

57.06 (25.58–149.40)

0.127

 CK-MB, ng/ml (IQR)

1.90 (1.20–3.51)

1.90 (1.20–3.53)

0.963

 CK, U/L (IQR)

67.50 (51.75–92.00)

70.00 (55.00–101.00)

0.051

 Scr, mg/dL (IQR)

0.85 (0.70–1.01)

0.86 (0.74–1.00)

0.135

 eGFR, ml/min/1.73m² (IQR)

91.24 (77.94–107.90)

91.27 (86.17–105.26)

0.082

 Ccr, mg/min (IQR)

78.34(60.89–96.49)

76.56 (62.08–90.06)

0.346

 BUN, mmol/L (IQR)

5.75 (4.85–6.47)

5.91 (4.77–6.85)

0.150

 Glu, mmol/L (IQR)

6.00 (5.28–6.90)

6.10 (5.20–7.33)

0.053

 HbA1c, % (IQR)

6.77 (6.20–7.20)

6.78 (6.10–7.40)

0.742

 TC, mmol/L (IQR)

3.50 (2.90–4.20)

3.47 (2.99–4.22)

0.547

 TG, mmol/L (IQR)

1.43 (0.99–1.70)

1.47 (1.03–1.47)

0.462

 LDL-C, mmol/L (IQR)

1.87 (1.38–2.48)

1.84 (1.44–2.46)

0.425

 HDL-C, mmol/L (IQR)

1.03 (0.88–1.20)

1.03 (0.98–1.12)

0.682

 ALT, U/L (IQR)

16.00 (13.00–25.25)

17.50 (13.00–24.00)

0.171

 AST, U/L (IQR)

18.00 (15.00–22.00)

18.00 (14.00–24.00)

0.126

 GGT, U/L (IQR)

32.00 (19.75–38.00)

36.00 (24.00–38.00)

0.155

 PLT, × 10⁹/L (IQR)

207.50 (175.25–242.75)

205.50 (174.75–244.25)

0.667

 MYO, ng/L (IQR)

27.45 (19.48–45.45)

30.30 (21.38–49.48)

0.123

 Hgb, g/L (IQR)

133.00 (122.00–144.25)

133.00 (121.75–143.00)

0.637

Description of the lesions

 Single-vessel disease, n (%)

79 (44.89)

93 (52.84)

0.135

 Multi-vessel disease (≥ 2), n (%)

97 (55.11)

83 (47.16)

0.135

 LM lesion, n (%)

5 (2.84)

4 (2.27)

1.000

 LCX lesion, n (%)

99 (56.25)

103 (58.52)

0.666

 LAD lesion, n (%)

45 (25.57)

38 (21.59)

0.379

 RCA lesion, n (%)

56 (31.82)

52 (29.55)

0.644

PCI information

 PCI with balloon only, n (%)

91 (51.71)

84 (47.73)

0.456

 PCI with stent only, n (%)

68 (38.64)

75 (42.62)

0.447

 PCI with balloon and stent, n (%)

17 (9.66)

17 (9.66)

1.000

 Contrast volume, mL (IQR)

156.50 (120.00–190.00)

152.50 (135.00–190.00)

0.778

Medications

 Antiplatelets, n (%)

175 (99.43)

172 (97.73)

0.371

 Anticoagulation, n (%)

2 (1.14)

4 (2.27)

0.685

 β-blockers, n (%)

134 (76.14)

136 (77.27)

0.801

 RAASi, n (%)

103 (58.52)

113 (64.21)

0.274

 CCB, n (%)

76 (43.18)

80 (45.46)

0.668

 ARNI, n (%)

39 (22.16)

39 (22.16)

1.000

 Statin, n (%)

157 (89.21)

162 (92.05)

0.361

 Ezetimibe, n (%)

67 (38.07)

70 (39.77)

0.743

 Diuretic, n (%)

50 (28.41)

53 (30.11)

0.725

 Metformin, n (%)

57 (32.39)

47 (26.71)

0.243

 DPP-4i, n (%)

31 (17.61)

34 (19.32)

0.680

 GLP-1RA, n (%)

12 (6.82)

12 (6.82)

1.000

 SU, n (%)

14 (7.96)

13 (7.39)

0.841

 Insulin, n (%)

51 (28.98)

43 (24.43)

0.335